Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page 0 w4 _9 _* b! M
; n* n- E7 z; D) t7 M* _& K" g. t) m
: ?/ A: h4 q, K- z4 F' c/ |Sub-category:
1 C* G2 H9 F4 |+ XMolecular Targets 8 Q9 q2 W) e- N, [2 @% e; |
1 s% G& r6 |1 b7 Z- v: Q8 F: ]
+ C- A# h; Y/ Y# Y3 f7 ] E
Category:) u# |: V' x1 R9 L1 Z5 L
Tumor Biology
0 M* r- h }3 w* w9 [5 f4 B# \- Y* K
* ]9 l1 ?" c" i) P" ~" q" PMeeting:
: H i5 w2 _# W! E. H2011 ASCO Annual Meeting
+ p9 q7 D1 U/ y; J8 {4 j5 K/ D0 u8 z+ Z
- G6 u: o/ t* C4 e5 u( _ Q" J# }. g. C* E
Session Type and Session Title:- i' z7 b0 c1 j9 N
Poster Discussion Session, Tumor Biology
0 G8 J7 a, s% ?( d1 [3 M* p) r
1 J- u/ v5 \8 Z" \" D
5 V9 |7 r- R9 X t) v8 B9 ^Abstract No:
1 G9 v8 ?/ v' W) x" x. C+ d10517
% {- S# t! H8 ~
: v: D, P8 F2 |6 i1 ~: Q# Z0 b9 D! |4 l2 `' E9 _8 f
Citation:
+ F, {& n" o) ~! oJ Clin Oncol 29: 2011 (suppl; abstr 10517)
5 e5 ~4 K1 m& g
- }; G0 |" N# Z9 m* i2 V# p, f5 ^4 I2 V5 A8 T6 |5 V' b
Author(s):4 T( t7 U% J$ a' h9 o
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
- F4 p8 `* ^" V. K4 l4 Y* H0 T7 H4 y) U& L7 `5 v8 Q# K8 c
" E7 ~# l; W4 `$ m- W& ]
) A6 Z) z% n' G' Z8 G0 D+ V
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
2 S+ H1 b* W% l h
B& _7 q" g4 o w' f, RAbstract Disclosures
2 w: M# h/ N; z# c; b8 p4 z4 `% a ]! C& N6 a6 z" @
Abstract:( y% |3 [7 Y. h$ x! j' \ x$ s
, h0 d! R7 j2 E* m9 q$ _# X! ?. m. W
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.5 n; c K! M3 C# R; O3 x* V
& U. f( _/ n( o5 W# ?% N |# R " f8 H9 W9 d3 x* X$ J- i
|
5 \% Y3 q% w N1 l, G
显身卡
